Tonghua Dongbao class of new drug URAT1 inhibitors declared clinical trials approved

On the evening of December 16, Tonghua Dongbao disclosed that its subsidiary Dongbao Zixing received a drug clinical trial approval notice on URAT1 inhibitors (THDBH130 tablets) issued by the Drug Evaluation Center of the State Drug Administration on December 15, with acceptance numbers CXHL2101548 and CXHL2101549.

THDBH130 tablets is a drug that targets URAT1 for the treatment of gout and hyperuricemia, and the THDBH130 tablets are approved for hyperuricemia and gout. Hyperuricemia is the basis of gout, but it is not enough to cause gout, which is often associated with obesity, diabetes, hypertension, hyperlipidemia, and cardiovascular and cerebrovascular diseases.

In recent years, China's hyperuricemia showed a significant rise and rejuvenation trend, in the existing treatment of gout drugs, URAT1 as the target of uric acid drugs are currently mainly benzbromarone and rescinald, of which rexinad has not yet been listed in China. According to the data of Yaozhi Network, the terminal benzbromomarone of public medical institutions will account for 15.91% of the share in 2020.

Chinese patients with hyperuricemia and gout have an urgent need for efficient and safe anti-gout drugs, tonghua Toho's URAT1 inhibitor, according to the existing experimental data, the product has a high effectiveness, selectivity and safety.

Firmly grasping the historical opportunity of the state to encourage innovative drugs, the company has strongly entered the field of innovative drugs on the basis of focusing on drug research and development in the field of diabetes and other important endocrine areas, and further enriched the research and development pipeline. In March this year, the company introduced three innovative drugs in the field of diabetes treatment, of which the world's first SGLT1/SGLT2/DPP4 three-target inhibitor was clinically approved in June, and the THDBH130 tablet clinical trial application was approved to further consolidate the company's progress in the field of gout research and development. At the same time, the approval of this clinical trial is also a further practice of the company's expansion in the field of large endocrine innovative drugs. (Liu Duo)